Bio-Techne Enhances Industry Engagement with December 2025 Investor Conferences

Bio-Techne Strengthens Industry Presence Through Strategic Engagements

Bio-Techne Corporation, a prominent player in the global life sciences sector, actively enhances its visibility and engagement with stakeholders by announcing its participation in three significant investor conferences in December 2025. This move signifies the company's commitment to fostering relationships within the investment community while showcasing its innovative contributions to research and clinical diagnostics. The conferences include the 8th Annual Evercore Healthcare Conference on December 2, the Citi 2025 Global Healthcare Conference on December 3, and the 53rd Annual Nasdaq Investor Conference on December 9. These events provide platforms for Bio-Techne to articulate its growth strategy and advancements in scientific tools that support drug discovery and disease diagnosis.

At these conferences, Bio-Techne emphasizes its diverse portfolio, which includes hundreds of thousands of bioactive reagents and tools designed to propel scientific research and clinical applications. The company reported impressive net sales exceeding $1.2 billion for fiscal 2025, underscoring its robust market position and the increasing demand for its products. By participating in these high-profile events, Bio-Techne aims to highlight its role as a catalyst for innovation in life sciences, particularly in the realms of research and diagnostics, where precision and reliability are paramount.

Bio-Techne’s presence at these conferences also reflects its strategic approach to investor relations. By providing live webcasts of its presentations, the company ensures transparency and accessibility for interested parties. This initiative not only reinforces Bio-Techne's accountability to its shareholders but also strengthens its reputation within the industry. With a workforce of approximately 3,100 dedicated professionals worldwide, the company remains focused on advancing scientific knowledge related to biological processes and the complexities of disease progression.

In addition to its conference participation, Bio-Techne continues to engage with the broader community through various digital channels. Interested stakeholders can explore the company's offerings and updates via its official website and social media platforms, including LinkedIn and YouTube. For investor inquiries, Bio-Techne encourages direct communication with David Clair, the Vice President of Investor Relations & Corporate Development, ensuring that stakeholders have access to the information they need.

Ultimately, Bio-Techne's active participation in these upcoming conferences illustrates its commitment to maintaining a leadership role in the life sciences sector, underlining its dedication to innovation and collaboration in advancing healthcare solutions.